share_log

SenesTech | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

SenesTech | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

SenesTech | S-8:員工福利計劃證券登記
美股SEC公告 ·  08/07 04:07

牛牛AI助理已提取核心訊息

SenesTech, Inc., a biotechnology company based in Delaware, has filed a Registration Statement with the U.S. Securities and Exchange Commission (SEC) on August 6, 2024, to register an additional 200,000 shares of common stock for issuance under its 2018 Equity Incentive Plan, as amended. This registration is in addition to the common stock previously registered under the plan through prior Registration Statements filed on various dates from 2018 to 2023. The company, which is classified as a non-accelerated filer and a smaller reporting company, incorporates by reference several documents including its Annual Report on Form 10-K for the year ended December 31, 2023, and its Quarterly Report for the quarter ended March 31, 2024. The filing includes the consent of its independent registered public accounting firm and legal counsel, and it is signed by key executives including President and CEO Joel L. Fruendt and CFO Thomas C. Chesterman.
SenesTech, Inc., a biotechnology company based in Delaware, has filed a Registration Statement with the U.S. Securities and Exchange Commission (SEC) on August 6, 2024, to register an additional 200,000 shares of common stock for issuance under its 2018 Equity Incentive Plan, as amended. This registration is in addition to the common stock previously registered under the plan through prior Registration Statements filed on various dates from 2018 to 2023. The company, which is classified as a non-accelerated filer and a smaller reporting company, incorporates by reference several documents including its Annual Report on Form 10-K for the year ended December 31, 2023, and its Quarterly Report for the quarter ended March 31, 2024. The filing includes the consent of its independent registered public accounting firm and legal counsel, and it is signed by key executives including President and CEO Joel L. Fruendt and CFO Thomas C. Chesterman.
生物技術公司SenesTech,Inc.總部位於特拉華州,於2024年8月6日向美國證券交易所(SEC)提交了一份註冊聲明,註冊額外的20萬股普通股以便根據其2018年股權激勵計劃作出發行。此次註冊是在2018年至2023年各個日期提交的先前註冊聲明下注冊的普通股之外的。該公司被歸類爲非加速交易商和較小的報告公司,通過引用若干文件包括其2013年12月31日年度報告和截至2024年3月31日的季度報告。備案文件包括其獨立的註冊會計師事務所和法律顧問的同意,並由總裁兼首席執行官Joel L. Fruendt和CFO Thomas C. Chesterman等關鍵高管簽署。
生物技術公司SenesTech,Inc.總部位於特拉華州,於2024年8月6日向美國證券交易所(SEC)提交了一份註冊聲明,註冊額外的20萬股普通股以便根據其2018年股權激勵計劃作出發行。此次註冊是在2018年至2023年各個日期提交的先前註冊聲明下注冊的普通股之外的。該公司被歸類爲非加速交易商和較小的報告公司,通過引用若干文件包括其2013年12月31日年度報告和截至2024年3月31日的季度報告。備案文件包括其獨立的註冊會計師事務所和法律顧問的同意,並由總裁兼首席執行官Joel L. Fruendt和CFO Thomas C. Chesterman等關鍵高管簽署。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。